Allo-HCT Improves Outcomes in Myelodysplastic Syndrome Across High-Risk Genetic Subgroups
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Myelodysplastic Syndrome Across High-Risk Genetic Subgroups: Genetic Analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 Study
J. Clin. Oncol 2023 Aug 22;[EPub Ahead of Print], J Versluis, W Saber, HK Tsai, CJ Gibson, LW Dillon, A Mishra, J McGuirk, RT Maziarz, P Westervelt, P Hegde, D Mukherjee, MJ Martens, B Logan, M Horowitz, CS Hourigan, R Nakamura, C Cutler, RC LindsleyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.